We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




China and India Challenge Pharmaceutical Giants to Improve their Healthcare Systems

By LabMedica International staff writers
Posted on 10 Sep 2012
Print article
Mature pharmaceutical markets such as the United States and the European Union (EU) countries are showing comparatively little change, in contrast to the quickly evolving healthcare markets of large emerging nations, China and India, according to a new market report.

The new report, published by healthcare market research company, GlobalData (London, UK), examined the extreme regulatory changes and economic growth experienced by these two countries that are bringing increased access to drugs and healthcare services for millions of citizens.

Recently, China has successfully transformed itself into the world’s second largest economy. China’s current five-year plan, setting policy for 2011-2015, was crafted with the goal of boosting research and development, especially in the biomedical sector, and reducing social inequality. The Chinese government is implementing a series of healthcare reforms, such as extending basic medical insurance coverage to cover 90% of the urban and rural population, and establishing an essential drug supply system to develop a unified distribution network. The plan to build 29,000 township hospitals, resulting in one hospital for each county, is to be met by the free training of general practitioners (GPs) and the recruitment of new doctors for rural areas.

India’s recent healthcare policies reflect China’s aim of caring for the country’s increasing population, by allowing billions of people to gain access to healthcare for the first time. In early March 2012, Prime Minister Manmohan Singh, who once described the country’s healthcare system as a “national shame,” announced plans for a massive increase in spending on healthcare. India now lags behind other developing countries in terms of healthcare outcomes, with a shockingly high rate of infant mortality and a 40% rate of child malnourishment. If the country is to build upon its recent economic gains, it must improve its healthcare system. India, similar to China, plans to invest in medical staff training, with a goal of opening 600 medical schools and 1,500 nursing colleges to train over one million doctors and 2.5 million nurses in an effort to lessen the country’s shortage of caregivers.

China and India have populations numbering billions, yet pharmaceutical pricing pressures are set to increase, and may foil the efforts of global companies to profit greatly from this potential moneymaker. The regulation of drug pricing represents a growing trend, with India granting its first compulsory license in March 2012, allowing local generics manufacturers to produce a generic version of Bayer’s patented cancer drug, Nexavar, in spite of intellectual property protections. Although China has not yet granted any compulsory licenses, it has announced an intention to do so in the future.

The reassurance of compulsory licensing presents a material risk to pharmaceutical drug sales, with Roche already taking preemptive steps to introduce less expensive versions of specific drugs in an attempt to control the abuse of their patents. GlobalData’s senior analyst for healthcare industry dynamics, Michael Leibfried, stated that, “the oncology giant has announced it will introduce cheaper, differently branded versions of certain drugs in India--preempting the issuance of compulsory licenses and could serve as a deterrent against the exportation of these drugs to markets that are more lucrative.”

Only the future will reveal whether these emerging countries will allow intellectual property to be upheld, or whether their goal for cost-effective public healthcare will challenge more laws and stymie corporate investment.

Related Links:

GlobalData



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The fastGEN BCR::ABL1 Cancer kit offers a way to personalize treatment strategies for leukemia (Photo courtesy of BioVendor MDx)

First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment

The BCR::ABL1 fusion gene plays a key role in the pathogenesis of several blood cancers, particularly chronic myeloid leukemia (CML). This gene results from a chromosomal translocation that causes constitutive... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.